Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer.
Harshabad SinghSamuel J KlempnerNelya MelnitchoukDeepak P ChanderOvidiu George NegreaAnuj K PatelBenjamin L SchlechterDouglas A RubinsonBrandon M HuffmanChetan NambiarJoshua RemlandElizabeth AndrewsMegan E LeahyLauren K BraisPeter C EnzingerHarvey J MamonMarios GiannakisJeffrey A MeyerhardtKimmie NgKimberley J PerezAndrew J AguirreJeffrey W ClarkJames M ClearyBrian M WolpinPublished in: JCO precision oncology (2023)
Quantitative tumor-informed serial ctDNA testing aids clinical management of patients with isolated peritoneal disease. Low levels of baseline ctDNA suggest a role for highly sensitive ctDNA approaches over panel-based testing. Further exploration of this approach should be considered in patients with isolated peritoneal malignant disease.